SCHEMBL279575

SCHEMBL279575

Cc1cccc(C(=O)NCC2CCCN2)c1

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.59
OPRM1 P35372 1/20 0.57
OPRK1 P41145 1/20 0.57
ROCK2 O75116 2/20 0.55
ROCK1 Q13464 1/20 0.55
NPC1 O15118 2/20 0.51
RAB9A P51151 2/20 0.51
PARP1 P09874 1/20 0.51
LMNA P02545 1/20 0.48
SCN9A Q15858 1/20 0.47
DRD2 P14416 1/20 0.47
ATM Q13315 1/20 0.47
HDAC8 Q9BY41 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
SYK P43405 2/20 0.46
KCNH2 Q12809 2/20 0.46
MAPK3 P27361 1/20 0.46
MAPK1 P28482 1/20 0.46
AURKB Q96GD4 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10380819 0.85 ROCK2 (0.58) HPGDROCK2ROCK1PARP1SCN9A
SCHEMBL279926 0.84 SCN9A (0.54) HPGDOPRM1ROCK2ROCK1NPC1
SCHEMBL31188482 0.84 ADRB1 (0.60) HPGDOPRM1ROCK2ROCK1PARP1
SCHEMBL5088410 0.84 ADRB1 (0.60) HPGDOPRM1ROCK2ROCK1PARP1
SCHEMBL8274391 0.84 ADRB1 (0.60) HPGDOPRM1ROCK2ROCK1PARP1
SCHEMBL8288130 0.83 ALDH1A1 (0.53) ROCK2ROCK1NPC1RAB9APARP1
SCHEMBL17790228 0.83 ROCK2 (0.61) ROCK2ROCK1PARP1SCN9ADRD2
SCHEMBL17094911 0.82 PARP1 (0.49) ROCK2ROCK1PARP1SCN9ADRD2
SCHEMBL13766311 0.81 PARP1 (0.61) OPRK1ROCK2ROCK1PARP1LMNA
SCHEMBL17788671 0.81 ROCK2 (0.59) ROCK2ROCK1PARP1SCN9ADRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
EP-1845090-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR Nissan Chemical Industries, Ltd. (JP) 2007-10-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR TEK, PTAFR, MPL HPGD 1895/4885OPRM1 616/4885OPRK1 1084/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.